365 related articles for article (PubMed ID: 22177248)
41. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
[TBL] [Abstract][Full Text] [Related]
42. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
Yan D; He Q; Chen Y; Wang L; Zhang X
J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Brychtova V; Zampachova V; Hrstka R; Fabian P; Novak J; Hermanova M; Vojtesek B
Exp Mol Pathol; 2014 Jun; 96(3):375-81. PubMed ID: 24747240
[TBL] [Abstract][Full Text] [Related]
44. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H; Alavian SM; Lankarani KB; Farrokh P; Randel Nyengaard J
Eur J Histochem; 2018 Jan; 62(1):2859. PubMed ID: 29569872
[TBL] [Abstract][Full Text] [Related]
45. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
46. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
47. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
48. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
49. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
51. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
[TBL] [Abstract][Full Text] [Related]
52. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
53. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
54. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
55. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
56. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
57. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
58. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
Liu JW; Zuo XL; Wang S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3655-73. PubMed ID: 26502856
[TBL] [Abstract][Full Text] [Related]
59. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.
Yao S; Zhang J; Chen H; Sheng Y; Zhang X; Liu Z; Zhang C
J Histochem Cytochem; 2013 Sep; 61(9):639-48. PubMed ID: 23686365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
